Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021
Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim
… strategy, which includes starting the Phase 2/3 trial for sepofarsen in LCA10 patients, initiating the first-in-human … (PRIME) program by the European Medicines Agency (EMA) for sepofarsen. The PRIME program is particularly focused on …
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned;Updated data from the Phase 1/2 InSight extension st
… retinal diseases (IRDs). The positive interim data for sepofarsen in LCA10 has resulted in our ability to move … blindness.” Corporate Highlights and Business Update Sepofarsen (formerly QR-110) for LCA10 In January 2019, …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… title: Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 … investigator of the ProQR Phase 1/2 clinical trial of sepofarsen Professor and Director of Vitreoretinal Diseases …
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10
Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020
QR-1123 Investigational New Drug application active for autosomal dominant re
… far with the initiation of both the Phase 2/3 trial for sepofarsen and the proof of concept trial for QR-421a in … to patients.” Corporate Highlights and Business Update Sepofarsen (formerly QR-110) for LCA10 In April 2019, the …
… Results Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when … outcome of the primary analysis in the Illuminate trial of sepofarsen, we believe that the post-hoc analyses and the …